A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

NCT06916091 | Completed Phase 1 FDA Drug

• 2 other identifiers: 27320J3R-MC-YDAD
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it. The study will last approximately 10 weeks excluding a screening period.

Conditions

Obesity; Overweight

Outcome Measures

Primary Outcomes (1)

• Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

  A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module

  Baseline to Study Completion (Up to 10 Weeks)

Secondary Outcomes (2)

• Pharmacokinetics (PK): Maximum Concentration (Cmax) of Eloralintide

  Baseline to Study Completion (Up to 10 Weeks)

• PK: Area Under the Concentration Versus Time Curve (AUC) of Eloralintide

  Baseline to Study Completion (Up to 10 Weeks)

Study Arms (2)

Eloralintide

EXPERIMENTAL

Eloralintide administered subcutaneously (SC)

Drug: Eloralintide

Placebo

PLACEBO COMPARATOR

Placebo administered SC

Drug: Placebo

Interventions

Eloralintide DRUG

Administered subcutaneously (SC)

Also known as: LY3841136

Eloralintide

Placebo DRUG

Administered SC

Placebo

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Chinese participants. To qualify as Chinese, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China
• Have had a stable body weight for 3 months prior to screening. Participants with body weight change of less than 5% will be allowed
• Have not modified diet or adopted any nutritional lifestyle modification for 3 months before randomization
• Have clinical laboratory test results within a normal range for the population or investigative site at screening and lead-in, or results with acceptable deviations that are judged to be not clinically significant by the investigator
• Have a body mass index (BMI) within the range 27 to 40 kilogram per square meter (kg/m²)

You may not qualify if:

• Are pregnant, or intend to become pregnant or to breastfeed during the study
• Have known allergies to related compounds of eloralintide
• Have any of the following abnormal blood pressure (BP) and/or pulse rate at screening, constituting a risk when taking the investigational product with minor deviations judged to be acceptable by the investigator:
• Supine BP \> 160/90 millimeter mercury (mmHg)
• Supine pulse rate \< 50 or \> 100 beats per minute (bpm)
• Orthostatic hypotension
• Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs
• Regularly use known drugs of abuse and/or show positive findings on drug screening that are not consistent with the medical history or concomitant medication history
• Have donated blood of more than 450 mL within the previous 3 months of study screening, or intend to donate blood during the course of the study
• Have a history of chronic medical conditions involving the heart, liver, or kidneys
• Have a medical history or current evidence of clinically significant cardiac condition

Sponsors & Collaborators

• Eli Lilly and Company: lead

Study Sites (1)

Lilly Centre for Clinical Pharmacology

Singapore, 138623, Singapore

Location

Related Links

• Related Info

MeSH Terms

Conditions

Obesity; Overweight

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Contact Lilly at 1-800-LillyRx (1-800-545-5979)

  Eli Lilly and Company

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 1, 2025
• First Posted: April 8, 2025
• Study Start: April 21, 2025
• Primary Completion: September 9, 2025
• Study Completion: September 9, 2025
• Last Updated: November 19, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

SG (1)